Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the ...

The healthcare leader is also an excellent income stock. Johnson & Johnson has increased its dividend payout for 62 ...

Duato discusses the split of the business, dealing with the scrutiny brought about by lawsuits, and 2025 priorities.

J&J IM, which this year marks two decades in Cork, was presented with the award at Cork Chamber’s annual dinner at City Hall ...

Lazari Capital Management Inc. raised its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 4.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC.

Boston Trust Walden Corp trimmed its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 0.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the ...

Johnson & Johnson's financial results are generally steady and consistent. Check out the chart of revenue and net income below. The company's balance sheet is rock solid and has earned it an AAA ...

Johnson & Johnson (NYSE: JNJ) is one of the world's largest and most prominent healthcare leaders. If investing in a company came down to size, the stock would be a no-brainer buy. However ...